Levotofisopam, the S-entantiomer of the racemic mixture RS-tofisopam, is said to be a well tolerated, effective, nonsedating agent used to treat various disorders related to stress or autonomic instability.
The trial follows two Phase 1 clinical studies that were completed by Vela Pharmaceuticals in collaboration with Pharmos in October 2006.
The previous studies showed that levotofisopam treatment was generally well tolerated and was associated with a large and rapid reduction in serum uric acid values.
Pharmos, which owns the rights to both R- and S-tofisopam, the two enantiomers of racemic tofisopam, through two US issued composition-of-matter patents, plans to seek a partner to further develop levotofisopam for the treatment of gout after completion of this proof-of-concept clinical trial.